Upon its launch, Anthos obtained the exclusive global rights to develop, manufacture, and commercialize abelacimab from Novartis.

Abelacimab is a novel monoclonal antibody under development for people with atrial fibrillation. The therapy locks Factor XI in the inactive state, resulting in dual inhibitory activity.